Extra-pulmonary Neuroendocrine Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-12-30
Clinical Trial Update: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating second-line therapy for progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma has completed.